Eli Lilly Alzheimers Drug Fails Major Test Trial A drug developed by Eli Lilly to treat patients with Alzheimers disease symptoms failed a closely watched clinical trial. WSJs Jeanne Whalen explains the impact of the failure on Eli Lilly stock and the rest of the pharmaceutical sector which had rested its hopes on the success of the drug. Photo: Kris Tripplaar/Sipa USA
#Media #Oligarchs #MegaBanks vs #Union #Occupy #BLM [VIDEO] Eli Lilly shares fall on Bernie Sanders tweet http://www.cnbc.com/2016/11/01/eli-lilly-shares-fall-on-bernie-sanders-tweet.html Shares of pharmaceutical company Eli Lilly initially fell more than 1 percent after Sen. Bernie Sanders tweeted Tuesday about the price of Lilly's Humalog insulin. Sanders shared a graphic from a story by The Washington Post that looks at why the price of insulin continues to rise. Eli Lilly's stock…
Eli Lilly (LLY), a major pharmaceutical company, is perhaps the best example. Not many people found Eli Lilly attractive in late 2010 because its stock wasn’t going up. Ironically, the stock has been on a tear ever since, gaining 159% on a total return basis. As a result, Eli Lilly’s valuation is now sky-high. The following chart shows Eli Lilly’s enterprise value-to-EBITDA multiple and price-to-sales ratio over the past 10 years.
Eli Lilly and Co. have announced that their experimental Alzheimer’s treatment has failed to slow mental deterioration in its latest study. Consequently, Lilly shares dropped 11.7 percent on Wednesday.